Initiation of coverage | ONXEO | A highly differentiated play in the DDR field
DNA Damage Response is a very interesting approach to treating cancer, which has become reality with the introduction of a first class of drugs known as PARP inhibitors. Not only have they created a market which is already worth USD2bn and still growing rapidly with the addition of new indications, but they have also been the subject of fierce M&A battles between large pharma companies. Pfizer outbid Sanofi to buy Medivation, GSK bought Tesaro and AZ shared Lynparza with Merck. In each case, billions of dollars were at stake.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.